While AraC treatment did not affect the cell cycle status of wild type leukemia cells expressing MLL-AF9, AraC treatment increased the number of Necdin null leukemia cells in the G0/G1 phase of the cell cycle and decreased the number of Necdin null leukemia cells in the S phase of the cell cycle (Figure 3F). Here, KMT2A is linked to leukemia.